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Abstract 
In order to determine whether hydroxyapatite modulates the response of polymorphonuclear leukocyte (PMN) to oxidative stimuli, human PMNs 
were incubated with a non-activating concentration (1 or 10 &ml) of hydroxyapatite prior to stimulation with N-formyl-methionyl-leucyl-phenyla- 
lanine (FMLP; 0.1 or 1 PM), phorbol 1Zmyristate 13-acetate (PMA; 100 pg/ml), sodium fluoride (50 PM), zymosan (1 &ml), or the calcium 
ionophore A23187 (0.1 PM). Chemiluminescence was measured with an automatic microcomputer-controlled luminescence analyzer at 37°C. 
Hydroxyapatite alone did not stimulate chemiluminescence at concentrations below 10 &ml. Levels 30&400% higher than ‘stimulus only’ controls 
without preincubation with hydroxyapatite have been recorded. This synergism between hydroxyapatite and subsequent stimuli reveals a new activity 
of hydroxyapatite and suggests that particulate material may prepare PMNs for an exaggerated inflammatory response to other phlogistic mediators. 
This is the first report demonstrating PMNs primed with particulate material. 
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1. Introduction 
The deposition of hydroxyapatite microcrystals in tis- 
sues is associated with pathological syndromes [l-3]. 
Clinical and experimental evidence of the fibrogenetic 
potential of hydroxyapatite particles seems to concur, in 
part, with data on the ability of the crystals to induce 
inflammatory cells to generate reactive oxygen meta- 
bolites in vitro. While hydroxyapatite crystals have been 
reported to induce a large array of biological effects 
[4-61, it is not known what concentration of the crystals 
would be necessary to induce pathological syndromes. 
The concentration of hydroxyapatite crystals is not so 
high even in an inflammatory joint. The concentrations 
of putative hydroxyapatite crystals found in the synovial 
fluid samples varied from about 3 to 18 ,@ml[7]. On the 
other hand, a high concentration of the crystals is usually 
needed to elicit a reaction in experimental models: 
2 mg/ml of hydroxyapatite crystals was needed to induce 
inflammation in a rat air-pouch model, an in vivo model 
[S] and 8 mg/ml of the crystals was necessary to elicit 
inflammation in an in vitro model [9]. Thus, hydrox- 
yapatite might have more physiological roles than origi- 
nally thought, one of them being modulation of inflam- 
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Abbreviations: PMNs, polymorphonuclear leukocytes; PBS, Dul- 
becco’s phosphate buffered saline; MEM, Dulbecco’s modified Eagle’s 
medium; PMA, phorbol 12-myristate 13-acetate; FMLP, N-formyl- 
methionyl-leucyl-phenylalanine. 
matory cells. However, the functional significance of hy- 
droxyapatite crystals is, at present, poorly understood. 
Because of the important role of the PMNs in re- 
sponses occurring in microcrystal-induced inflammation 
[lo], we studied the in vitro effects of hydroxyapatite on 
PMNs. In this report, we show that hydroxyapatite 
primes PMNs for enhanced chemiluminescence in re- 
sponse to subsequent stimuli. 
2. Materials and methods 
2.1. Materials 
All chemicals were purchased from the Sigma Chemical Co. (St. 
Louis, MO, USA) unless indicated. For this study, hydroxyapatite was 
prepared by Mitsubishi Materials Co., Tokyo, Japan, as described 
previously [ll]. Briefly, it was prepared using a slow precipitation 
method, and sintered at 1200°C. The crystals were ground down to the 
desired particle size. The protein content of these particles was checked 
by the direct Ninhydrin reaction and Bradford’s method using Coomas- 
sie brilliant blue [12]. No trace of protein appeared. The crystals, all 
buffers and reconstituted reagents were verified to be pyrogen-free by 
the limulus amebocyte lysate assay (Sigma Co., St. Louis, MO) follow- 
ing FDA guidelines [13]. All solutions used were determined to contain 
less than 10 pgfml of contaminating endotoxin with the exception of the 
Ficoll-Hypaque separation medium that contained less than 20 pg/ml 
of contaminating endotoxin. However, this is still less than the reported 
100 pg/ml or more of lipopolysaccharide required to prime PMNs for 
enhanced reactive oxygen metabolites [14]. Confirmation of crystal 
structure and purity was obtained by high resolution X-ray powder 
diffraction with monochromatic CuKa radiation on a rotating anode 
X-ray generator (Rigaku, Model RU-200 and RINT-2400, Tokyo, 
Japan). Patterns were compared to a known hydroxyapatite standard. 
The X-ray diffraction patterns of this synthetic hydroxyapatites showed 
the apatite peaks. Infrared spectra were made of the specimens on an 
Infrared spectrum’s analyzer (Shimadzu, Model FTIR-4000, Kyoto, 
Japan) operating in the absorbance mode. The specimens exhibited 
apparently symmetric 63G640 cm-’ OH- stretch peaks. 
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2.2. Particle measurements 
Crystal sizes were determined using a particle size analyzer 
(Shimadzu, Model SALD-1100, Kyoto, Japan). The average diameter 
of the crystal was 3.0 pm. About 3 pm was chosen because of our 
previous study as described previously [11,15]. The surface areas were 
measured with a surface area analyzer (Yuasa-Ionics Corp., Model 
Monosorb. MS- 13, Osaka, Japan). One-point Brunauer-Emmett-Teller 
(BET) surface area determinations were made using nitrogen (adsor- 
bate) in helium (carrier) gas mixtures. The specific surface area for the 
hydroxyapatite was 6.2 m’/g. The zeta potential (a measure of the 
crystal surface charge ) was determined using a zeta potential analyzer 
(Penkem, System-3000) for the hydroxyapatite samples suspended in 
distilled water. The average zeta potential was -12.2 mV. 
2.3. PMNs isolation 
PMNs were isolated by Ficoll-Hypaque density centrifugation from 
heparinized human venous blood, obtained from apparently healthy 
adults. PMNs were removed separately, washed in Dulbecco’s phos- 
phate buffered saline (PBS). and counted. More than 98% of the cells ,_ 
were PMNs, as assessed from Wright-Gimsa stained smears. 
2.4. Priming of PMNs with hydroxyapatite 
PMNs (5 x lo5 cells/ml) were preincubated in Dulbecco’s modified 
Eagle’s medium (MEM) at 37°C for varying periods of time with 
hydroxyapatite particles suspended in PBS or PBS alone. At the end 
of the pretreatment time, cells were determined to be z 97% viable by 
the exclusion of Trypan blue. PMN clumping did not occur, as deter- 
mined by microscopy of cells in suspension. Each stimulus for chemilu- 
minescence was added without removal of the hydroxyapatite particles. 
2.5. Chemiluminesrence assay 
Chemiluminescence was measured in quadruplicate or pentaplicate 
reaction mixtures, as previously described [1 I], with an automatic mi- 
crocomputer-controlled luminescence analyzer (LB 953, Berthold, Ger- 
many) at 37°C. The emission curve by each stimulation was recorded 
continuously for 90 min. Results were expressed as counts per minute 
(cpm) per 5 x 10’ cells, which showed the chemiluminescence intensity 
integrated from 0 to 90 min. To measure hydroxyapatite-triggered 
chemiluminescence, PMNs (5 x 10’ cells/ml) were incubated with lumi- 
no1 (5-amino, 2,3-dihydro l,4-phthalazine-dione, 10m4 M, Tokyo Kasei 
Kogyo, Tokyo, Japan) and hydroxyapatite particles. To measure hy- 
droxyapatite-priming for enhanced chemiluminescence in response to 
triggered by each stimulus, PMNs (5 x 10’ cells/ml) were preincubated 
with hydroxyapatite particles for varying periods of time, and then 
luminol and each stimulus were added. The following stimuli at 
pre-determined optimal concentrations were used. (i) N-formyl- 
methionyl-leucyl-phenylalanine (FMLP; 0.1 or 1 PM), (ii) phorbol l2- 
myristate 13-acetate (PMA; 100 pg/ml), (iii) sodium fluoride (50 PM), 
(iv) zymosan (1 &ml), and (v) the calcium ionophore A23 187 (0.1 PM). 
Cell-free reaction mixtures with hydroxyapatite caused no chemilumi- 
nescence responses. 
2.6. Statistical analysis 
The number (n) of separate experiments from which the data were 
derived is indicated in the figure legends. Data are expressed as the 
mean values f standard error of the mean (S.E.M.). One factor analysis 
of variance (ANOVA) with repeated measures was used to determine 
significance between controls and test groups. Differences between 
treatment means were determined by the Scheffe procedure. The 0.05 
level was used as the criterion of statistical significance. 
3. Results 
Fig. 1 shows the chemiluminescence r sponse, i.e. the 
production of reactive oxygen metabolites, induced by 
hydroxyapatite particles in human PMNs. Hydrox- 
yapatite caused a dose-related activation of PMN chem- 
iluminescence that was statistically significant at concen- 
trations of 1,000 ,&ml and greater. Hydroxyapatite at 
all concentrations tested did not activate chemilumines- 
cence without PMNs. 
The priming effects of low-concentrations of hydrox- 
yapatite (less than 10 &ml) on FMLP-induced PMN 
chemiluminescence are shown in Fig. 2. The effects were 
maximal at 10 &ml of hydroxyapatite. Hydroxyapatite 
priming of PMNs occurred in a concentration-dependent 
manner. Concentrations of hydroxyapatite that enhance 
0.1 PM FMLP-induced chemiluminescence were 2-10 
&ml. Concentrations of hydroxyapatite that enhance 
1 ,uM FMLP-induced chemiluminescence were 0.2-10 
pg/ml: 10 &ml hydroxyapatite stimulated chemilumi- 
nescence at 0.1 PM or 1 PM of FMLP by 354% or 753%, 
respectively. The degree of enhancement of FMLP-in- 
duced oxidative metabolism was dependent on the length 
of time the PMNs were incubated with hydroxyapatite 
(Fig. 3). A maximum (sevenfold) increase in chemilumi- 
nescence occurred when PMNs were incubated with hy- 
droxyapatite for 2 h and longer before addition of FMLP 
(Fig. 3). 
The priming effects of low concentrations of hydrox- 
yapatite (0.1-10 ,&ml) on PMA-, sodium fluoride-, zy- 
mosan- and calcium ionophore-induced PMN chemilu- 
minescence are shown in Fig. 4. They were maximal at 
2 &ml with PMA or sodium fluoride, and at 10 pg/ml 
with zymosan or the calcium ionophore A23187. Prein- 
cubation of PMNs with 10 ,@ml hydroxyapatite en- 
hanced the oxidative burst response of these cells to 
PMA, sodium fluoride, zymosan, or A23187 by 1,354%, 
659%, 651% or 316%, respectively. 
4. Discussion 
We found that hydroxyapatite alone stimulated the 
PMN respiratory burst but only at high concentrations 
above 1,000 pg/ml, in agreement with previous reports 
[9]. We also demonstrated, for the first time, that prein- 
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Fig. 1. Effect of varying concentrations of hydroxyapatite on the inte- 
gral chemiluminescence responses of PMNs. Chemiluminescence is ex- 
pressed as the mean f S.E.M., n = 5. A statistically significant differ- 
ence compared with controls is designated by ‘(P < 0.05). 
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Fig. 2. The priming effect of hydroxyapatite on FMLP-induced PMN 
chemiluminescence. PMNs were preincubated in the absence or pres- 
ence of hydroxyapatite at concentrations of 0.1 to 10 &ml for 60 min 
at 37°C and stimulated with 0.1 ,uM (0) or 1 PM (0) of FMLP. Results 
are expressed as a % of control values, i.e. chemiluminescence in the 
absence of hydroxyapatite. Control values were 1,213,333 t 98,928 and 
2,134,667 f 234,069 for 0.1 and 1 PM of FMLP, respectively 
(means f S.E.M., n = 4). A statistically significant difference between 
experiments performed in the absence (control) and in the presence of 
hydroxyapatite, is designated by *(P < 0.05). 
cubating human PMNs with hydroxyapatite results in 
enhanced chemiluminescence upon subsequent stimula- 
tion by various agents. Levels 300-1, 400% higher than 
‘stimulus only’ controls have been recorded. The priming 
response, defined as a greater than additive effect of the 
two agonists alone, is a common feature for most agents 
which activate PMNs [16]. The priming response is elic- 
ited by a variety of agents such as adenosine 5’-tri- 
phosphate (ATP) [ 171, endotoxin [ 141, stimulatory lipids 
such as platelet-activating factor (PAF) [ 181, oleoyl-ace- 
tyl-glycerol (OAG) [ 191, arachidonic metabolites [ 181, 
and phorbol esters [20]. However, previous studies on 
priming have been described only for soluble agents, 
except for influenza virus [21]. Bautista et al. [22] demon- 
strated that activation of the liver reticuloendothelial sys- 
tem by in vivo latex phagocytosis enhances the produc- 
tion of oxygen-derived radicals by these cells: they only 
showed the indirect evidence of the priming effect by an 
insoluble agent. Our studies here directly examined the 
potential of an insoluble agent, hydroxyapatite particles, 
to induce enhanced chemiluminescence. These results de- 
monstrate that hydroxyapatite can be added to the grow- 
ing list of agents capable of modulating the respiratory 
burst response of PMNs. 
The priming response is associated with a number of 
events such as degradation, receptor up-regulation, in- 
crease in intracellular calcium, and the production of 
lipid second messengers. Walker and Ward [16] group 
priming agents into two categories: receptor-dependent 
and -independent priming. The priming of PMNs by 
receptor-ligand interactions can be subdivided into two 
15 
groups. The rapid onset of the primed state shown in Fig. 
3 suggests that the priming of PMNs by hydroxyapatite 
may belong to the first type, in which agonists produce 
transient increases in intracellular calcium, with re- 
sponses being mediated by a pertussis toxin-sensitive sig- 
nal transduction pathway. 
Although the significance of these in vitro observa- 
tions to hydroxyapatite-induced iseases has yet to be 
fully established, they suggest the following clinical 
possibility and relationship to the development of hy- 
droxyapatite-induced arthritis and joint loosening after 
artificial arthroplasty with implants containing hydrox- 
yapatite. PMNs are involved in the inflammatory proc- 
ess in arthritis and joint loosening, and oxygen radicals 
are known to cause tissue damage. During the spread of 
hydroxyapatite particles into the lesions, PMNs become 
primed. Consequently, recruitment of leukocytes to the 
lesion will include primed PMNs that have a greater 
inflammatory potential. As the priming effects of low- 
concentrations of hydroxyapatite on PMN chemilumi- 
nescence induced by various stimuli were preserved (Fig. 
4), the enhanced generation of oxygen radicals from 
primed PMNs may play a role in the pathogenesis of 
tissue damage in hydroxyapatite-induced arthritis and 
joint loosening after implants containing hydrox- 
yapatite. We have demonstrated two distinct dose-re- 
lated interactions of hydroxyapatite with human PMNs: 
low-dose priming and high-dose activation of oxidant 
generation. Since the concentrations of hydroxyapatite 
vary in location, it is probable that both priming and 
stimulating interactions of hydroxyapatite with human 
CON 0 60 120 160 240 300 
Time (min) 
Fig. 3. Effect of length of preincubation with hydroxyapatite on FMLP- 
induced PMN chemiluminescence. PMNs were preincubated (37°C) for 
various periods of time with 1 @ml of hydroxyapatite or buffer (PBS). 
Results are expressed as a 8 of control values, i.e. chemiluminescence 
in the absence of hydroxyapatite, at each time before addition of 1 PM 
of FMLP. Control value (CON) without preincubation with hydrox- 
yapatite was 1,128,633 k 27,954 (means k S.E.M, n = 4). A statistically 
significant difference between experiments performed in the absence 
(control) and in the presence of hydroxyapatite at each time, is desig- 
nated by *(P < 0.05). 
16 M. Nagase et al.IFEBS Letters 349 (1994) 13-16 
0.1 0.2 1 2 
HA P(ug/ml) 
10 
Fig. 4. Priming effect of hydroxyapatite on PMA-, sodium fluoride-, 
zymosan-, and calcium ionophore-induced PMN chemiluminescence. 
PMNs were preincubated in the absence or presence of hydroxyapatite 
at concentrations from 0.1 to 10 &ml for 60 min at 37°C and stimu- 
lated with 100 pg/ml (L) of PMA, 50pM (0) of sodium fluoride, 1 &ml 
(1) of zymosan, or 0.1 PM (A) of the calcium ionophore A23187. 
Results are expressed as a % of control values, i.e. chemiluminescence 
in the absence of hydroxyapatite. Control values were 
1,124,333 +40,683, 2,151,OOO + 84,524, 2,650,OOO + 89,790 and 
10,776,667 + 289,620 for PMA, sodium fluoride, zymosan, and calcium 
ionophore, respectively (means + S.E.M., n = 4). A statistically signifi- 
cant difference between experiments performed in the absence (control) 
and in the presence of hydroxyapatite, is designated by *(P < 0.05). 
phagocytes occur in vivo. These interactions of hydrox- 
yapatite with human PMNs may implicate the lower 
concentration of particles in actual inflammatory sites [7] 
compared to experimental models [8,9]. We may have 
been able to see only the direct hydroxyapatite-induced 
inflammation in previous experimental models. 
In conclusion, we first demonstrated that preincu- 
bating human PMNs with hydroxyapatite results in an 
enhanced chemiluminescence upon subsequent stimula- 
tion by various agents. We also presented the possibility 
that the PMNs primed by low-dose hydroxyapatite are 
important as one of the causes of hydroxyapatite-in- 
duced arthritis and joint loosening after artificial arthro- 
plasty with implants containing hydroxyapatite. 
Additional studies may elucidate the exact role of the 
hydroxyapatite-primed PMNs in the pathogenesis of the 
tissue damages. 
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